← Back to Clinical Trials
Recruiting NCT07379866

NCT07379866 Glossopharyngeal and Maxillary Nerve Blocks in Adenotonsillectomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07379866
Status Recruiting
Phase
Sponsor Cairo University
Condition Regional
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2026-01
Primary Completion 2026-05

Eligibility & Interventions

Sex All sexes
Min Age 5 Years
Max Age 13 Years
Study Type INTERVENTIONAL
Interventions
ultrasound-guided glossopharyngeal nerve block (UGSGNB)ultrasound-guided maxillary nerve (UGMN)Placebo Block

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2026-01 with a primary completion date of 2026-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to compare of bilateral ultrasound-guided glossopharyngeal nerve (UGGNB) and ultrasound-guided maxillary nerve (UGMNB) versus conventional multimodal analgesia for tonsillectomy operations.

Eligibility Criteria

Inclusion Criteria: * Pediatric patients aged 5 to 13 years * American Society of Anesthesiologists (ASA) physical status I-II scheduled for adenotonsillectomy. Exclusion Criteria: * Parents Refusal * Cognitive impairment or developmental delays. * Infection at injection site. * Recent upper respiratory tract infection. * Post-tonsillectomy bleeding, allergy to local anesthetics. * American Society of Anesthesiologists (ASA) class III and IV. * Morbid obesity. * Those receiving regular analgesia within the last week before surgery.

Contact & Investigator

Central Contact

Nagy Malak, MD

✉ nagymalak12345@gmail.com

📞 +201552480258

Principal Investigator

Nagy malak, MD

PRINCIPAL INVESTIGATOR

Cairo University

Frequently Asked Questions

Who can join the NCT07379866 clinical trial?

This trial is open to participants of all sexes, aged 5 Years or older, up to 13 Years, studying Regional. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07379866 currently recruiting?

Yes, NCT07379866 is actively recruiting participants. Contact the research team at nagymalak12345@gmail.com for enrollment information.

Where is the NCT07379866 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT07379866 clinical trial?

NCT07379866 is sponsored by Cairo University. The principal investigator is Nagy malak, MD at Cairo University. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology